Article
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
The New England journal of medicine - 24 Sept 2020
Hong David S, Fakih Marwan G, Strickler John H, Desai Jayesh, Durm Gregory A, Shapiro Geoffrey I, Falchook Gerald S, Price Timothy J, Sacher Adrian, Denlinger Crystal S, Bang Yung-Jue, Dy Grace K, Krauss John C, Kuboki Yasutoshi, Kuo James C, Coveler Andrew L, Park Keunchil, Kim Tae Won, Barlesi Fabrice, Munster Pamela N, Ramalingam Suresh S, Burns Timothy F, Meric-Bernstam Funda, Henary Haby, Ngang Jude, Ngarmchamnanrith Gataree, Kim June, Houk Brett E, Canon Jude, Lipford J Russell, Friberg Gregory, Lito Piro, Govindan Ramaswamy, Li Bob T
Abstract excerpt
BACKGROUND: No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C. METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.